Clinical implications of polymers and lipids in designing drug delivery systems in geriatric use by Sai Raj Kappari
Sai Raj Kappari., (2020) Int. J. Res. Hos & Clin. Pharm., 2(3), 66-70 
66   © Rubatosis Publications | International Journal of Research In Hospital and Clinical Pharmacy 
 
 
International Journal of Research in Hospital 
and Clinical Pharmacy 
 
Clinical implications of polymers and lipids in designing drug delivery systems in geriatric use 
Sai Raj Kappari 
ABSTRACT 
 
This paper will emphasize some of the clinical implications of polymers and lipids in designing drug delivery 
systems in the geriatric population. This article will give us an overview of the advantages and disadvantages 
of polymers and lipids in formulating DDS in individuals over 65 in the United States.  Lipid polymer hybrids 
can be advantageous in systemic drug bioavailability to patients who have decreased drug carrier capacity. 
Older adults may benefit from lipid polymer hybrids as it enhances drug delivery and drug targeting process.  
Most of the older adults use a minimum of 4 to 6 medications for a variety of medical ailments and 
conditions. Polypharmacy may be an advent situation in some of the cases, which can be reduced by 
innovative drug delivery options. 
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INTRODUCTION 
In the United States, the population age 65 and over 
numbered over 56.4 million in 2020 (estimated for 
which data are available) and represents 16% of the 
total population [1]. The average life expectancy of in-
dividuals has increased over the decades and it is 78.9 
years. Women tend to outlive men over 4 years on av-
erage [2]. Older adults have a minimum of one chronic 
condition and many have multiple chronic conditions 
(Shah et.al., 2017) [3,4]. The top five chronic ailments 
were hypertension (58%), hyperlipidemia (47%), ar-
thritis (30%), Ischemic Heart Disease (28%), and di-
abetes (26%) [5]. Individuals on average take 4 to 6 
medications daily and have seen by a doctor two to 
three times a year. Older adults tend to take vaccina-
tions more than the general population especially the 
pneumococcal (70%) and influenza (73%) [6,7]. More 
than 30% of individuals over 65 are obese. Physical 
activity is followed by close to half of the individuals 
in 65 to 74 age groups and only 26% of people over 
75 engage in any physical activity [8,9]. Older adults av-
erage more office visits with a doctor or other health 
care professionals than young individuals [10]. People 
who are over 75 about 25% have 10 or more visits to 
a doctor in a year. The majority of individuals over 65 
have Medicare or Medicaid insurance [11,12]. Body me-
tabolism decreases as we age and an individual's reg-
ular physiological activities decrease which affects all 
the organ systems [13,14]. A series of functionalities are 
lost in tissue and cellular levels as individual age [15, 
16, 17]. 
Trends in the use of polymers and lipids in drug 
delivery systems for geriatrics 
Lipid and Polymer hybrids may improve the drug bi-
oavailability in the vulnerable population due to a de-
crease in the body's physiological activities (Lasic, 
2001) [18, 19]. The release of drug to a systemic site can 
increase the drug activity that can decrease the drug 
side effect impact on the individuals with decreasing 
glomerular filtration rate [20, 21]. As individuals age the 
GFR reduces through age and the condition can be 
considered normal for higher age even the rate is 30 
ml/min (Glassock & Winearls, 2009) [22, 23].  Targeted 
drug release can lower the risk of drug-food and 
drug-drug interaction [24]. Oral administration of 
medications may be less effective as the gastric activ-
ity is reduced with age. Polypharmacy can be mini-
mized when drugs are taken through a special mode 
of administration improving the therapeutic index 
while reducing side effects. Successfully targeting 
specific cells for the release of the payload of drugs 
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can benefit older adults at a higher rate than the reg-
ular means of medication administration [25, 26]. 
These lipid-polymer hybrids are prominent in build-
ing confidence in the modern approach to improving 
the health and wellbeing of individuals [27, 28, 29].  
These hybrids are beneficial for the enhancement of 
oral absorption and bioavailability, targeting delivery 
systems, effectively increasing biological membrane 
permeability, on-site release, and overcoming the 
polypharmacy aspect of multiple drug resistance in 
the older adult population [30, 31, 32]. 
Clinical implications by using lipid/polymer-
based delivery systems for geriatrics 
Older adults are easily susceptible to disease condi-
tions especially infections that are caused due to re-
duced immune response [33, 34, 35]. There are inade-
quate evidence and knowledge about how geriatric 
patients respond to liposome-polymer hybrid and the 
effectiveness of any medication at large given the 
overall condition of the physiology of an older adult, 
most clinical trials omit testing individuals over 65 
(Fahy et.al., 2011) [36, 37, 38, 39, 40]. 
Geriatric individuals can respond differently than the 
younger generations to drug targeted therapy [41, 42, 
43]. Pharmacokinetics and Pharmacodynamics are af-
fected due to age-related physiological changes, 
which are inevitable as reversing age is not possible 
[44, 45, 46]. Older adults are at a higher risk to develop 
adverse effects due to concomitant drugs and comor-
bidities (Clark, 2015) [47, 48, 49]. Nanoparticles such as 
the lipid polymer hybrids may deplete or reduce pul-
monary function, as they are easily permeable into 
the human body and carried across by systemic cir-
culation [50, 51]. The mode of administration of drug 
and therapeutic index plays a pivotal role in bringing 
a focused approach to the therapy of a particular ail-
ment [52, 53], and it may or may not be successful in an 
individual with comorbid conditions and most of the 
older adults have these conditions (Bartlam, Lally 
and Crome, 2010) [54, 55, 56]. These lipid-polymer hy-
brids may benefit individuals who have an earlier di-
agnosis of any form of cancer or life-sustaining condi-
tions, provided the benefit does not overtake the risk 
(Hutchins, 1999) [57, 58, 59, 60].  
CONCLUSION 
In conclusion, lipid-polymer hybrids are some most 
sophisticated approaches in drug delivery systems [61, 
62, 63]. which can enhance and improve the quality of 
therapeutic advancements in treating geriatric pa-
tients [64, 65, 66]. The procedural conduct may increase 
over time with enhancements in modern therapies. 
Most of the clinical studies are conducted on the indi-
vidual with an inclusion criterion between 18 to 64 
years [67, 68, 69] In recommendation we can educate 
older adults on the importance of being part of these 
studies in creating novel models for all generations[70, 
71]. 
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